Workshop Series Workshop Series

Overcoming Challenges in the Treatment of Relapsed/Refractory Multiple Myeloma


Released:
5/1/13
Expires:
7/12/14

Maximum Credits:

2.5

Workshop Series Workshop Series
Released:
5/1/13

Expires:
7/12/14

Maximum Credits:
2.5
Workshop Series Workshop Series

Released:
5/1/13
Expires:
7/12/14


Maximum Credits:
2.5


Overview: This interactive workshop provides hematology/oncology clinicians with strategies to guide therapeutic decision making for patients with relapsed/refractory multiple myeloma. It features small-group case discussions to illustrate practical solutions for addressing issues associated with managing this stage of disease.

Workshop Dates/Locations:

Chicago—July 20, 2013
Hyatt Regency O'Hare, 9300 Bryn Mawr Avenue, Rosemont, IL


Houston—July 13, 2013
The Houstonian, 111 North Post Oak Lane, Houston, TX


New York—August 3, 2013
W New York Union Square, 201 Park Avenue South, New York, NY


San Francisco—July 27, 2013
The Westin St. Francis on Union Square, 335 Powell Street, San Francisco, CA


Registration is free. Reserve your seat today by completing this brief online form, calling (toll-free) 866 858 7434, or e-mailing info@med-iq.com. For the complete workshop agenda, click on the “Details” tab above.

Faculty

Rafael Fonseca, MD

Getz Family Professor of Cancer

Chair, Department of Medicine

Mayo Clinic

Scottsdale, AZ

Sagar Lonial, MD

Professor and Vice Chair of Clinical Affairs

Department of Hematology and Medical Oncology

Director of Translational Research, B-Cell Malignancy Program

Winship Cancer Institute

Emory University School of Medicine

Atlanta, GA


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Rafael Fonseca, MD
Consulting fees/advisory boards: Celgene Corporation, Genzyme, Lilly USA, LLC, Onyx Pharmaceuticals
Other (Research Grants): Celgene Corporation, Onyx Pharmaceuticals
 
Sagar Lonial, MD
Consulting fees/advisory boards: Bristol-Myers Squibb, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals
 
Joseph Mikhael, MD, MEd, has indicated no real or apparent conflicts.

Keith Stewart, MB, ChB
Consulting fees/advisory boards: Celgene Corporation, Genentech, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals


The activity planner and peer reviewers have no financial relationships to disclose.


This activity is supported by educational grants from Celgene Corporation, Takeda Oncology, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.